Atopic Dermatitis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Atopic Dermatitis – Pipeline Review, H1 2017’, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects

The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Accolade Pharmaceuticals LLC

Albireo Pharma Inc

Almirall SA

Amgen Inc

Amorepacific Corp

AnaptysBio Inc

AnGes MG Inc

Antibiotx ApS

Avexxin AS

Blueberry Therapeutics Ltd

Brickell Biotech Inc

Celgene Corp

Cell Medica Ltd

Cellceutix Corp

ChemoCentryx Inc

ChironWells GmbH

Chugai Pharmaceutical Co Ltd

Clevexel Pharma SA

Curapel Ltd

Cutanea Life Sciences Inc

Dermala Inc

Dr. August Wolff GmbH & Co KG Arzneimittle

Eli Lilly and Company

Exicure Inc

F. Hoffmann-La Roche Ltd

Foamix Pharmaceuticals Ltd

Fountain Biopharma Inc

Galapagos NV

Galectin Therapeutics Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Grupo Ferrer Internacional SA

GTx Inc

Han Wha Pharma Co Ltd

HanAll Biopharma Co Ltd

Heptares Therapeutics Ltd

Herantis Pharma Plc

iCo Therapeutics Inc.

Immune Pharmaceuticals Inc

Incyte Corp

Inflamalps SA

Japan Tobacco Inc

Kang Stem Biotech Co Ltd

KPI Therapeutics Inc

LEO Pharma A/S

Madam Therapeutics BV

MedImmune LLC

NeoPharm Co Ltd

Novan Inc

Novartis AG

Orbis Biosciences Inc

Otsuka Holdings Co Ltd

Oxagen Ltd

Pfizer Inc

Pharis Biotec GmbH

Pharmedartis GmbH

Provectus Biopharmaceuticals Inc

Qurient Co Ltd

Realm Therapeutics Plc

Regeneron Pharmaceuticals Inc

Roivant Sciences Ltd

Signum Biosciences Inc

Signum Dermalogix Inc

Spherium Biomed SL

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

SWITCH Biotech LLC

Thesan Pharmaceuticals Inc

Torrent Pharmaceuticals Ltd

Trevi Therapeutics Inc

Valeant Pharmaceuticals International Inc

Vicore Pharma AB

Vitae Pharmaceuticals Inc

VivaCell Biotechnology Espana SL

Xencor Inc

Zhejiang I-Biological Technology Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Atopic Dermatitis - Overview 12

Atopic Dermatitis - Therapeutics Development 13

Pipeline Overview 13

Pipeline by Companies 14

Pipeline by Universities/Institutes 20

Products under Development by Companies 21

Products under Development by Universities/Institutes 28

Atopic Dermatitis - Therapeutics Assessment 29

Assessment by Target 29

Assessment by Mechanism of Action 33

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Atopic Dermatitis - Companies Involved in Therapeutics Development 41

AbbVie Inc 41

Accolade Pharmaceuticals LLC 41

Albireo Pharma Inc 42

Almirall SA 42

Amgen Inc 43

Amorepacific Corp 43

AnaptysBio Inc 44

AnGes MG Inc 44

Antibiotx ApS 45

Avexxin AS 45

Blueberry Therapeutics Ltd 46

Brickell Biotech Inc 46

Celgene Corp 47

Cell Medica Ltd 47

Cellceutix Corp 48

ChemoCentryx Inc 48

ChironWells GmbH 49

Chugai Pharmaceutical Co Ltd 49

Clevexel Pharma SA 50

Curapel Ltd 50

Cutanea Life Sciences Inc 51

Dermala Inc 51

Dr. August Wolff GmbH & Co KG Arzneimittle 52

Eli Lilly and Company 52

Exicure Inc 53

F. Hoffmann-La Roche Ltd 53

Foamix Pharmaceuticals Ltd 54

Fountain Biopharma Inc 54

Galapagos NV 55

Galectin Therapeutics Inc 55

GlaxoSmithKline Plc 56

Glenmark Pharmaceuticals Ltd 56

Grupo Ferrer Internacional SA 57

GTx Inc 57

Han Wha Pharma Co Ltd 58

HanAll Biopharma Co Ltd 58

Heptares Therapeutics Ltd 59

Herantis Pharma Plc 59

iCo Therapeutics Inc. 60

Immune Pharmaceuticals Inc 60

Incyte Corp 61

Inflamalps SA 61

Japan Tobacco Inc 62

Kang Stem Biotech Co Ltd 62

KPI Therapeutics Inc 63

LEO Pharma A/S 63

Madam Therapeutics BV 64

MedImmune LLC 64

NeoPharm Co Ltd 65

Novan Inc 65

Novartis AG 66

Orbis Biosciences Inc 66

Otsuka Holdings Co Ltd 67

Oxagen Ltd 67

Pfizer Inc 68

Pharis Biotec GmbH 68

Pharmedartis GmbH 69

Provectus Biopharmaceuticals Inc 69

Qurient Co Ltd 70

Realm Therapeutics Plc 70

Regeneron Pharmaceuticals Inc 71

Roivant Sciences Ltd 71

Signum Biosciences Inc 72

Signum Dermalogix Inc 72

Spherium Biomed SL 73

sterna biologicals Gmbh & Co KG 73

Sun Pharma Advanced Research Company Ltd 74

SWITCH Biotech LLC 74

Thesan Pharmaceuticals Inc 75

Torrent Pharmaceuticals Ltd 75

Trevi Therapeutics Inc 76

Valeant Pharmaceuticals International Inc 76

Vicore Pharma AB 77

Vitae Pharmaceuticals Inc 77

VivaCell Biotechnology Espana SL 78

Xencor Inc 78

Zhejiang I-Biological Technology Co Ltd 79

Atopic Dermatitis - Drug Profiles 80

A-3914 - Drug Profile 80

A-5425 - Drug Profile 81

AKP-11 - Drug Profile 82

Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 84

ALX-101 - Drug Profile 85

AMG-0101 - Drug Profile 86

Anatabine - Drug Profile 88

ANB-020 - Drug Profile 91

Antisense Oligonucleotide to Antagonize IL-4RA for Atopic Dermatitis - Drug Profile 93

apremilast - Drug Profile 94

Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 106

ARN-077 - Drug Profile 107

AVX-001 - Drug Profile 108

AZT-01 - Drug Profile 110

B-244 - Drug Profile 111

baricitinib - Drug Profile 113

BB-2702 - Drug Profile 123

BBI-2000 - Drug Profile 124

BBI-5000 - Drug Profile 125

bertilimumab - Drug Profile 126

betamethasone valerate - Drug Profile 130

Biologic for Atopic Dermatitis - Drug Profile 131

Biologic for Atopic Dermatitis and Eczema - Drug Profile 132

brilacidin tetrahydrochloride - Drug Profile 133

BTX-1204 - Drug Profile 144

C-21 - Drug Profile 145

CBP-174 - Drug Profile 148

CBP-201 - Drug Profile 149

CCX-6239 - Drug Profile 150

CDE-001 - Drug Profile 151

Cis-Urocanic Acid - Drug Profile 152

cobamamide - Drug Profile 154

CT-101 - Drug Profile 156

CT-103 - Drug Profile 157

CVXL-0074 - Drug Profile 158

cyclosporin - Drug Profile 159

cyclosporine - Drug Profile 160

dalazatide - Drug Profile 161

DMT-210 - Drug Profile 166

Drug for Atopic Dermatitis - Drug Profile 168

Drug for Atopic Dermatitis - Drug Profile 169

dupilumab - Drug Profile 170

FB-825 - Drug Profile 179

fevipiprant - Drug Profile 180

FIB-116 - Drug Profile 182

FM-1202 - Drug Profile 183

Furestem-AD - Drug Profile 184

GBR-830 - Drug Profile 185

GLPG-2534 - Drug Profile 186

GRMD-02 - Drug Profile 187

GSK-3772847A - Drug Profile 200

Gtx-186 - Drug Profile 201

Histimex - Drug Profile 202

house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile 203

HS-378 - Drug Profile 204

IDP-124 - Drug Profile 205

INV-25 - Drug Profile 206

INV-88 - Drug Profile 207

JTE-052 - Drug Profile 208

K-1032 - Drug Profile 209

KPI-150 - Drug Profile 210

lebrikizumab - Drug Profile 211

LEKTI-6 - Drug Profile 215

LP-0058 - Drug Profile 216

LP-0108 - Drug Profile 217

LP-0145 - Drug Profile 218

LP-0155 - Drug Profile 219

MEDI-9314 - Drug Profile 220

mepolizumab - Drug Profile 221

MLR-1130 - Drug Profile 227

mometasone furoate - Drug Profile 228

Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 229

Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 230

MOR-106 - Drug Profile 231

MSB-01 - Drug Profile 233

nalbuphine hydrochloride ER - Drug Profile 234

nemolizumab - Drug Profile 238

niclosamide - Drug Profile 240

NPB-311 - Drug Profile 242

NPH-12 - Drug Profile 243

OC-2417 - Drug Profile 244

octenidine hydrochloride - Drug Profile 245

OLX-103 - Drug Profile 246

omiganan pentahydrochloride - Drug Profile 247

OPA-15406 - Drug Profile 250

P-10 - Drug Profile 252

P-148 - Drug Profile 253

PAC-14028 - Drug Profile 254

Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 256

Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 257

PF-04965842 - Drug Profile 258

PF-06817024 - Drug Profile 259

PH-10 - Drug Profile 260

PL-601 - Drug Profile 263

PMA-101R - Drug Profile 264

PMA-201 - Drug Profile 265

PMA-411R - Drug Profile 266

PR-022 - Drug Profile 267

prednisone - Drug Profile 269

PZ-235 - Drug Profile 270

ruxolitinib phosphate - Drug Profile 271

RVT-201 - Drug Profile 286

RVT-501 - Drug Profile 287

SB-011 - Drug Profile 289

SB-414 - Drug Profile 290

secukinumab - Drug Profile 291

SIG-1322 - Drug Profile 305

SIG-1451 - Drug Profile 306

Small Molecule for Atopic Dermatitis - Drug Profile 307

Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 308

Small Molecules for Atopic Dermatitis - Drug Profile 309

Small Molecules for Atopic Dermatitis - Drug Profile 310

Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 311

SNA-120 - Drug Profile 312

SNA-125 - Drug Profile 315

SUN-0597 - Drug Profile 316

SWT-01113 - Drug Profile 318

SWT-05141 - Drug Profile 319

Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 320

tacrolimus - Drug Profile 321

tezepelumab - Drug Profile 322

tralokinumab - Drug Profile 324

upadacitinib tartrate - Drug Profile 327

VTP-38543 - Drug Profile 330

WBI-1001 - Drug Profile 332

WOL-071007 - Drug Profile 334

XmAb-7195 - Drug Profile 335

YJC-10592 - Drug Profile 337

Zafi-1 - Drug Profile 338

zafirlukast - Drug Profile 339

zileuton - Drug Profile 340

ZPL-389 - Drug Profile 341

ZPL-521 - Drug Profile 343

Atopic Dermatitis - Dormant Projects 344

Atopic Dermatitis - Discontinued Products 350

Atopic Dermatitis - Product Development Milestones 351

Featured News & Press Releases 351

Appendix 364

Methodology 364

Coverage 364

Secondary Research 364

Primary Research 364

Expert Panel Validation 364

Contact Us 364

Disclaimer 365

List of Tables

List of Tables

Number of Products under Development for Atopic Dermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Atopic Dermatitis – Pipeline by AbbVie Inc, H1 2017

Atopic Dermatitis – Pipeline by Accolade Pharmaceuticals LLC, H1 2017

Atopic Dermatitis – Pipeline by Albireo Pharma Inc, H1 2017

Atopic Dermatitis – Pipeline by Almirall SA, H1 2017

Atopic Dermatitis – Pipeline by Amgen Inc, H1 2017

Atopic Dermatitis – Pipeline by Amorepacific Corp, H1 2017

Atopic Dermatitis – Pipeline by AnaptysBio Inc, H1 2017

Atopic Dermatitis – Pipeline by AnGes MG Inc, H1 2017

Atopic Dermatitis – Pipeline by Antibiotx ApS, H1 2017

Atopic Dermatitis – Pipeline by Avexxin AS, H1 2017

Atopic Dermatitis – Pipeline by Blueberry Therapeutics Ltd, H1 2017

Atopic Dermatitis – Pipeline by Brickell Biotech Inc, H1 2017

Atopic Dermatitis – Pipeline by Celgene Corp, H1 2017

Atopic Dermatitis – Pipeline by Cell Medica Ltd, H1 2017

Atopic Dermatitis – Pipeline by Cellceutix Corp, H1 2017

Atopic Dermatitis – Pipeline by ChemoCentryx Inc, H1 2017

Atopic Dermatitis – Pipeline by ChironWells GmbH, H1 2017

Atopic Dermatitis – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by Clevexel Pharma SA, H1 2017

Atopic Dermatitis – Pipeline by Curapel Ltd, H1 2017

Atopic Dermatitis – Pipeline by Cutanea Life Sciences Inc, H1 2017

Atopic Dermatitis – Pipeline by Dermala Inc, H1 2017

Atopic Dermatitis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017

Atopic Dermatitis – Pipeline by Eli Lilly and Company, H1 2017

Atopic Dermatitis – Pipeline by Exicure Inc, H1 2017

Atopic Dermatitis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Atopic Dermatitis – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Atopic Dermatitis – Pipeline by Fountain Biopharma Inc, H1 2017

Atopic Dermatitis – Pipeline by Galapagos NV, H1 2017

Atopic Dermatitis – Pipeline by Galectin Therapeutics Inc, H1 2017

Atopic Dermatitis – Pipeline by GlaxoSmithKline Plc, H1 2017

Atopic Dermatitis – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Atopic Dermatitis – Pipeline by Grupo Ferrer Internacional SA, H1 2017

Atopic Dermatitis – Pipeline by GTx Inc, H1 2017

Atopic Dermatitis – Pipeline by Han Wha Pharma Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by Heptares Therapeutics Ltd, H1 2017

Atopic Dermatitis – Pipeline by Herantis Pharma Plc, H1 2017

Atopic Dermatitis – Pipeline by iCo Therapeutics Inc., H1 2017

Atopic Dermatitis – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Atopic Dermatitis – Pipeline by Incyte Corp, H1 2017

Atopic Dermatitis – Pipeline by Inflamalps SA, H1 2017

Atopic Dermatitis – Pipeline by Japan Tobacco Inc, H1 2017

Atopic Dermatitis – Pipeline by Kang Stem Biotech Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by KPI Therapeutics Inc, H1 2017

Atopic Dermatitis – Pipeline by LEO Pharma A/S, H1 2017

Atopic Dermatitis – Pipeline by Madam Therapeutics BV, H1 2017

Atopic Dermatitis – Pipeline by MedImmune LLC, H1 2017

Atopic Dermatitis – Pipeline by NeoPharm Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by Novan Inc, H1 2017

Atopic Dermatitis – Pipeline by Novartis AG, H1 2017

Atopic Dermatitis – Pipeline by Orbis Biosciences Inc, H1 2017

Atopic Dermatitis – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by Oxagen Ltd, H1 2017

Atopic Dermatitis – Pipeline by Pfizer Inc, H1 2017

Atopic Dermatitis – Pipeline by Pharis Biotec GmbH, H1 2017

Atopic Dermatitis – Pipeline by Pharmedartis GmbH, H1 2017

Atopic Dermatitis – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Atopic Dermatitis – Pipeline by Qurient Co Ltd, H1 2017

Atopic Dermatitis – Pipeline by Realm Therapeutics Plc, H1 2017

Atopic Dermatitis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Atopic Dermatitis – Pipeline by Roivant Sciences Ltd, H1 2017

Atopic Dermatitis – Pipeline by Signum Biosciences Inc, H1 2017

Atopic Dermatitis – Pipeline by Signum Dermalogix Inc, H1 2017

Atopic Dermatitis – Pipeline by Spherium Biomed SL, H1 2017

Atopic Dermatitis – Pipeline by sterna biologicals Gmbh & Co KG, H1 2017

Atopic Dermatitis – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Atopic Dermatitis – Pipeline by SWITCH Biotech LLC, H1 2017

Atopic Dermatitis – Pipeline by Thesan Pharmaceuticals Inc, H1 2017

Atopic Dermatitis – Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Atopic Dermatitis – Pipeline by Trevi Therapeutics Inc, H1 2017

Atopic Dermatitis – Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Atopic Dermatitis – Pipeline by Vicore Pharma AB, H1 2017

Atopic Dermatitis – Pipeline by Vitae Pharmaceuticals Inc, H1 2017

Atopic Dermatitis – Pipeline by VivaCell Biotechnology Espana SL, H1 2017

Atopic Dermatitis – Pipeline by Xencor Inc, H1 2017

Atopic Dermatitis – Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017 (Contd..2), H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017 (Contd..3), H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017 (Contd..4), H1 2017

Atopic Dermatitis – Dormant Projects, H1 2017 (Contd..5), H1 2017

Atopic Dermatitis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Atopic Dermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports